SCHEMBL4159852

SCHEMBL4159852

NCc1ccc(Cc2ccccn2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
LOX P28300 1/20 0.49
HRH1 P35367 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
CYP2E1 P05181 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2A6 P11509 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2B6 P20813 2/20 0.42
CYP2C19 P33261 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
HRH4 Q9H3N8 1/20 0.40
CYP2D6 P10635 1/20 0.40
LMNA P02545 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16598083 0.79 HRH3 (0.44) HRH1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL4159850 0.76 HPGD (0.48) HRH1L3MBTL1SMN1; SMN2NPC1RAB9A
SCHEMBL27420733 0.75 L3MBTL1 (0.42) HRH1L3MBTL1CYP2C19SMN1; SMN2NPC1
SCHEMBL29375684 0.74
SCHEMBL10672099 0.74 HRH1 (0.67) MAOAMAOBHRH1L3MBTL1SMN1; SMN2
SCHEMBL40328 0.74
SCHEMBL31063816 0.74 EPHX2 (0.50) MAOAMAOBHRH1L3MBTL1SMN1; SMN2
SCHEMBL41191 0.73 L3MBTL1 (0.59) MAOAMAOBHRH1L3MBTL1SMN1; SMN2
SCHEMBL29830938 0.73 L3MBTL1 (0.59) MAOAMAOBHRH1L3MBTL1SMN1; SMN2
SCHEMBL1145968 0.73 KDM4E (0.64) MAOAMAOBLOXL3MBTL1CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD MAOA 1732/4885MAOB 2220/4885LOX 3392/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 MAOA 538/4885MAOB 1205/4885LOX 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.